BeaconEquity.com announces the publication of an article covering Cellceutix’s filing for patent protection for its new cancer drug candidate, Kevetrin ™, and similar compounds.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“Cellceutix Corp. (OTCBB: CTIX) announced it has filed for patent protection with the U.S. Patent and Trademark Office covering pharmaceutical formulations for the company's new cancer drug candidate, Kevetrin ™, and similar compounds. The company said the various compounds cover possible drug candidates for the treatment of cancer and other related pathologies.”
Additional compounds covered by the patent application are structurally very different from anti-cancer agents currently on the market, states Cellceutix CEO:
“’This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market,’ George Evans, CEO of Cellceutix stated in the press release. ‘Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures.’”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
